These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 17968315

  • 21. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells.
    Su L, Liu G, Hao X, Zhong N, Zhong D, Liu X, Singhal S.
    Eur J Cancer; 2011 Nov; 47(16):2471-8. PubMed ID: 21726997
    [Abstract] [Full Text] [Related]

  • 22. Isoobtusilactone A sensitizes human hepatoma Hep G2 cells to TRAIL-induced apoptosis via ROS and CHOP-mediated up-regulation of DR5.
    Chen CY, Yiin SJ, Hsu JL, Wang WC, Lin SC, Chern CL.
    J Agric Food Chem; 2012 Apr 04; 60(13):3533-9. PubMed ID: 22400995
    [Abstract] [Full Text] [Related]

  • 23. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH, de Vries EG, Meersma GJ, Hougardy BM, van der Zee AG, de Jong S.
    Int J Radiat Oncol Biol Phys; 2008 Oct 01; 72(2):543-52. PubMed ID: 18793956
    [Abstract] [Full Text] [Related]

  • 24. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
    Shin YK, Park JS, Kim HS, Jun HJ, Kim GE, Suh CO, Yun YS, Pyo H.
    Cancer Res; 2005 Oct 15; 65(20):9501-9. PubMed ID: 16230415
    [Abstract] [Full Text] [Related]

  • 25. Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae.
    Martin S, Phillips DC, Szekely-Szucs K, Elghazi L, Desmots F, Houghton JA.
    Cancer Res; 2005 Dec 15; 65(24):11447-58. PubMed ID: 16357153
    [Abstract] [Full Text] [Related]

  • 26. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
    Kardosh A, Golden EB, Pyrko P, Uddin J, Hofman FM, Chen TC, Louie SG, Petasis NA, Schönthal AH.
    Cancer Res; 2008 Feb 01; 68(3):843-51. PubMed ID: 18245486
    [Abstract] [Full Text] [Related]

  • 27. 3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5.
    Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S.
    Carcinogenesis; 2006 Apr 01; 27(4):717-28. PubMed ID: 16332727
    [Abstract] [Full Text] [Related]

  • 28. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
    Xie H, Gao L, Chai N, Song J, Wang J, Song Z, Chen C, Pan Y, Zhao L, Sun S, Wu K, Feitelson MA, Liu J, Fan D.
    Mol Carcinog; 2009 Jan 01; 48(1):56-65. PubMed ID: 18506760
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2α/CHOP-dependent manner.
    Moon DO, Asami Y, Long H, Jang JH, Bae EY, Kim BY, Choi YH, Kang CH, Ahn JS, Kim GY.
    Toxicol In Vitro; 2013 Feb 01; 27(1):257-63. PubMed ID: 22982206
    [Abstract] [Full Text] [Related]

  • 31. ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1.
    Oh YT, Liu X, Yue P, Kang S, Chen J, Taunton J, Khuri FR, Sun SY.
    J Biol Chem; 2010 Dec 31; 285(53):41310-9. PubMed ID: 21044953
    [Abstract] [Full Text] [Related]

  • 32. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y, Zhang B.
    Mol Cancer Res; 2008 Dec 31; 6(12):1861-71. PubMed ID: 19074831
    [Abstract] [Full Text] [Related]

  • 33. TRAIL death receptors and cancer therapeutics.
    Huang Y, Sheikh MS.
    Toxicol Appl Pharmacol; 2007 Nov 01; 224(3):284-9. PubMed ID: 17240413
    [Abstract] [Full Text] [Related]

  • 34. Apoptosis of murine lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: molecular mechanisms and therapeutic potential.
    Yang P, Zhang Y, Ping L, Gao XM.
    Int Immunopharmacol; 2007 Nov 01; 7(11):1414-21. PubMed ID: 17761345
    [Abstract] [Full Text] [Related]

  • 35. TRAIL as a target in anti-cancer therapy.
    Wu GS.
    Cancer Lett; 2009 Nov 18; 285(1):1-5. PubMed ID: 19299078
    [Abstract] [Full Text] [Related]

  • 36. Green tea polyphenol stimulates cancer preventive effects of celecoxib in human lung cancer cells by upregulation of GADD153 gene.
    Suganuma M, Kurusu M, Suzuki K, Tasaki E, Fujiki H.
    Int J Cancer; 2006 Jul 01; 119(1):33-40. PubMed ID: 16463383
    [Abstract] [Full Text] [Related]

  • 37. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
    Gasparian ME, Chernyak BV, Dolgikh DA, Yagolovich AV, Popova EN, Sycheva AM, Moshkovskii SA, Kirpichnikov MP.
    Apoptosis; 2009 Jun 01; 14(6):778-87. PubMed ID: 19412666
    [Abstract] [Full Text] [Related]

  • 38. Death receptor 5 promoter-enhancing compounds isolated from Catimbium speciosum and their enhancement effect on TRAIL-induced apoptosis.
    Ohtsuki T, Kikuchi H, Koyano T, Kowithayakorn T, Sakai T, Ishibashi M.
    Bioorg Med Chem; 2009 Sep 15; 17(18):6748-54. PubMed ID: 19682913
    [Abstract] [Full Text] [Related]

  • 39. Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
    Li S, Tong Q, Zhang W, Wang Q, Chen Z, Wu Q.
    Cancer Invest; 2008 May 15; 26(4):333-7. PubMed ID: 18443952
    [Abstract] [Full Text] [Related]

  • 40. Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines.
    Gradilone A, Silvestri I, Scarpa S, Morrone S, Gandini O, Pulcinelli FM, Gianni W, Frati L, Aglianò AM, Gazzaniga P.
    Oncol Rep; 2007 Apr 15; 17(4):823-8. PubMed ID: 17342322
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.